Janney Montgomery Scott LLC Acquires Shares of 61,319 Elanco Animal Health Incorporated (NYSE:ELAN)

Janney Montgomery Scott LLC bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELANFree Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 61,319 shares of the company’s stock, valued at approximately $913,000.

Several other large investors have also recently made changes to their positions in the business. Treasurer of the State of North Carolina raised its holdings in Elanco Animal Health by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 221,460 shares of the company’s stock worth $2,489,000 after acquiring an additional 1,107 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Elanco Animal Health by 10.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock worth $181,000 after purchasing an additional 1,127 shares during the period. Ieq Capital LLC grew its position in Elanco Animal Health by 10.8% in the 3rd quarter. Ieq Capital LLC now owns 13,464 shares of the company’s stock worth $151,000 after purchasing an additional 1,311 shares during the period. AMG National Trust Bank grew its position in Elanco Animal Health by 1.1% in the 3rd quarter. AMG National Trust Bank now owns 122,526 shares of the company’s stock worth $1,377,000 after purchasing an additional 1,332 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in Elanco Animal Health by 2.6% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 61,540 shares of the company’s stock worth $692,000 after purchasing an additional 1,546 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ELAN. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, May 9th. Piper Sandler reissued a “neutral” rating and set a $19.00 price objective (up previously from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group boosted their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.29.

Get Our Latest Stock Analysis on Elanco Animal Health

Insider Buying and Selling

In related news, Director R David Hoover purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now directly owns 185,000 shares in the company, valued at $2,985,900. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director William F. Doyle purchased 15,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were acquired at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the purchase, the director now directly owns 76,330 shares in the company, valued at $1,296,083.40. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director R David Hoover purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was bought at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now owns 185,000 shares in the company, valued at $2,985,900. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Trading Up 1.0 %

Shares of Elanco Animal Health stock opened at $17.58 on Friday. The company has a market capitalization of $8.69 billion, a P/E ratio of -6.63, a P/E/G ratio of 1.66 and a beta of 1.34. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29. The company has a fifty day moving average of $15.30 and a 200 day moving average of $14.85. Elanco Animal Health Incorporated has a fifty-two week low of $7.88 and a fifty-two week high of $17.82.

Elanco Animal Health (NYSE:ELANGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. Elanco Animal Health’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Stories

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANFree Report).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.